-
2023-509566-38-00
9
2024-08-05
gastroesophageal junction adenocarcinoma
-
2022-501105-12-00
5
2024-07-15
Urothelial Carcinoma
-
2022-500030-28-01
4
2024-06-10
Urothelial carcinoma
-
2022-501606-35-01
11
2024-02-21
Platinum-sensitive epithelial ovarian, fallopian tube, or primary
peri
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2025-522805-39-00
4
2026-02-06
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
-
2025-521606-18-00
4
2026-01-29
Ovarian Cancer
-
2024-519494-19-00
5
2025-12-22
Nutritional and metabolic diseases
-
2024-519712-13-00
5
2025-12-08
Hypertriglyceridemia (HTG)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-519976-19-00
5
2025-11-26
Asthma with type 2 inflammation characterized by an eosinophilic pheno
-
2024-520190-12-00
5
2025-11-10
Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2025-520981-23-00
4
2025-08-26
Idiopathic Hypersomnia (IH)
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance